Featured Research

from universities, journals, and other organizations

Game changer for leukemia therapy may lead to less clinical treatment

Date:
June 10, 2014
Source:
University of Adelaide
Summary:
Researchers are zeroing in on a promising new approach to killing off cancer cells in patients with leukemia. Researchers have found that cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment.

Australian researchers are zeroing in on a promising new approach to killing off cancer cells in patients with leukemia.

Related Articles


In a study led by the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide's Centre for Personalised Cancer Medicine, researchers have found that cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment.

The researchers say this study presents a new treatment strategy which will translate to a significant reduction in side effects for patients. The results have been published online ahead of print in the journal Leukemia.

"This discovery is paradigm shifting," says Professor Deborah White, Director, Cancer Research with SAHMRI and University of Adelaide professor. "Our findings are not just applicable to chronic myeloid leukemia (CML) therapy, but to all targeted cancer treatments.

"In our research, we're looking for methods that will result in the cancer cell killing itself. This would provide an improved treatment and reduce the risk of cancer relapse."

As a consequence of this finding, Professor White and colleagues identified a new target in resistant and persistent disease. They show that by blocking a common protein they can more effectively cause death in leukemia cells.

Professor White and her research team, including University of Adelaide PhD student Lisa Schafranek, have been investigating the role of a common protein known as STAT5.

"The activity of STAT5 appears to be a critical determinant of the decision for cancer cells to live or die," says Miss Schafranek, a Leukemia Foundation of Australia PhD scholar.

"Our research has found that by blocking STAT5 in conjunction with exposure to a regular anti-cancer treatment, we were able to more effectively target the leukemia cells. We now also better understand the timing required for the combined treatment to be effective."


Story Source:

The above story is based on materials provided by University of Adelaide. Note: Materials may be edited for content and length.


Journal Reference:

  1. L Schafranek, E Nievergall, J A Powell, D K Hiwase, T Leclercq, T P Hughes, D L White. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 2014; DOI: 10.1038/leu.2014.156

Cite This Page:

University of Adelaide. "Game changer for leukemia therapy may lead to less clinical treatment." ScienceDaily. ScienceDaily, 10 June 2014. <www.sciencedaily.com/releases/2014/06/140610100257.htm>.
University of Adelaide. (2014, June 10). Game changer for leukemia therapy may lead to less clinical treatment. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/06/140610100257.htm
University of Adelaide. "Game changer for leukemia therapy may lead to less clinical treatment." ScienceDaily. www.sciencedaily.com/releases/2014/06/140610100257.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins